Megan Hoffman on Adding the Nurse's Voice to Pharmacogenomics

Video

Megan Hoffman, MSN, RN, CMSRN, AOCNS, discusses the importance of having a nurse's perspective when discussing genomics and precision medicine.

Megan Hoffman, MSN, RN, CMSRN, AOCNS, of Moffitt Cancer Center, discusses the nurse’s perspective that she brings to the Clinical Genomic Action Committee (CGAC) at her center.

Many members of the CGAC work mainly behind the scenes and often never see patients. As the nurse member, Hoffman brought patient concerns such as quality of life issues and family concerns into the discussion. This helped the board narrow options based on the feasibility and truly make a wholly individualized recommendation.

Recent Videos
Anne M. Reb, PhD, NP, discussing a nurse-led intervention for fear of cancer recurrence.
Ann H. Partridge, MD, MPH, in an interview with Oncology Nursing News at 2024 ESMO Congress.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Opinion: Liquid Biopsy and Tissue Testing Yield Comparable Results for ROS1 in NSCLC

Opinion: Liquid Biopsy and Tissue Testing Yield Comparable Results for ROS1 in NSCLC

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
August 19th 2024
Article

Oncology nurses play a crucial role in educating patients about the significance of liquid biopsy in diagnosis and its use in evaluating resistance.

Breast Cancer Survivors May Not Undergo Genetic Testing, Counseling Regardless of Eligibility

Breast Cancer Survivors May Not Undergo Genetic Testing, Counseling Regardless of Eligibility

Roman Fabbricatore
August 16th 2024
Article

Genetic testing offers potential benefits after a cancer diagnosis by potentially reducing the risk for cancer in families with hereditary cancer syndromes and managing treatment.

dna genetics genomic tests © marina zlochin -adobe.stock.com.png

Out-of-Pocket Costs, Insurance Status May Impact Genomic Testing Rates

Kyle Doherty
April 10th 2024
Article

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

lung cancer

Should You Wait for NGS Results Before Initiating NSCLC Treatment?

Lindsay Fischer
November 17th 2023
Article

Beth Sandy, MSN, CRNP, and Tajuana Bradley, MSN, APRN-BC, discuss the importance of molecular testing in non–small cell lung cancer.

Are At-Home Genomic Tests Such as 23andMe Ethical?

Are At-Home Genomic Tests Such as 23andMe Ethical?

Lindsay Fischer
September 22nd 2023
Article

Cheryl VerStrate, DNP, AGPCNP-BC, OCN, explains the pitfalls with at-home genomic tests and why nurses must be ready to talk to their patients about genetic counseling.

nurse with patient

Increase in Direct-to-Consumer Genomic Testing Yields New Ethical Considerations for Oncology Nurses

Lindsay Fischer
August 10th 2023
Article

Oncology nurses make the case for nurse intervention with direct-to-consumer genomic testing.

© 2024 MJH Life Sciences

All rights reserved.